Device Trial Radar · NCT04936425
Comparison of Stent Suturing Versus OTSC Stentfix
Last checked: Nov 20, 2026Latest source record: Jun 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jul 21, 2023
Primary completion
Jul 31, 2024
Study completion Jul 31, 2025
Sponsor
- Lead sponsor
- NYU Langone HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 23, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate whether OTSC stentfix is a feasible, safe, and efficient device that can be used for esophageal stent fixation (to prevent stent migration) in patients with benign, non-stricture esophageal lesions, including leaks, perforation, and fistulae. Currently, self-expandable metal stents (SEMS) have a risk of migration which can lead to adverse events such as bleeding and perforation. There has been clinical experience demonstrating that stent suturing can prevent stent migration. However, stent suturing can significantly increase endoscopic procedural time. The use of OTSC stentfix for stent fixation is promising as it is likely less time-consuming and less technically difficult, with likely a similar rate of fixation and migration. This non-inferiority study aims to investigate how OTSC stentfix functions as compared to stent suturing. If OTSC stentfix is at least comparable to stent suturing, it can reduce endoscopy procedural times, minimize peri-endoscopic risks, and minimize adverse events related to stent migration.
Conditions
- Esophageal Stent Fixation
Interventions
OTSC StentfixDevice
The OTSC stentfix will be placed during upper endoscopy after a self-expanding metal stent has been deployed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average rate of stent migrationTime frame: 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NYU Langone Health
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.